# US 2014/0194310 A1 · Genes dysregulated in autism as biomarkers and targets for therapeutic pathways > Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt - Number: US 2014/0194310 A1 - Document ID: US20140194310A1 - Status: Published application - Kind: A1 - Application number: 14/119,755 - Filed: 2012-05-24 - Published: 2014-07-10 - Earliest claimed: 2011-05-24 - Inventors: Daniel H. Geschwind; Irina Voineagu - Web page: https://patentgrep.com/patent/US20140194310A1 ## CPC - C12Q 1/6883: for diseases caused by alterations of genetic material - C12Q 2600/136: Screening for pharmacological compounds - C12Q 2600/158: Expression markers - C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES ## Abstract The disclosed invention comprises methods and materials for screening cells for genetic profiles associated with autism spectrum disorders. The methods typically involve isolating a cell from an individual and then observing the expression profile of one or more genes in the cell, wherein certain expression patterns of the genes observed are associated with autism spectrum disorders. ## Claims ### Claim 1 A method of identifying a test mammalian cell having a gene expression profile observed in individuals diagnosed with autism comprising: observing an expression profile of at least one gene comprising a sequence selected from the group consisting of SEQ ID NOs: 1-44 in the test mammalian cell; wherein an expression profile of a gene in the group that is at least two standard deviations from a mean expression profile of the gene in a control mammalian cell obtained from an individual not affected with autism identifies the test mammalian cell as having a gene expression profile observed in individuals diagnosed with autism. ### Claim 2 (depends on 1) The method of claim 1, wherein the expression of a gene in the group is at least three, four or five standard deviations from the mean expression of the gene observed in a control mammalian cell. ### Claim 3 (depends on 1) The method of claim 1, wherein the expression level of a gene in the group is at least 20, 30, 40, 50, 60 or 70% above or below the expression level of the gene observed in the control mammalian cell. ### Claim 4 (depends on 1) The method of claim 1, wherein mRNA expression is observed. ### Claim 5 (depends on 4) The method of claim 4, wherein the expression profile is observed using: (a) a microarray of polynucleotides; and/or (b) a quantitative PCR (qPCR) process. ### Claim 6 (depends on 1) The method of claim 1, wherein an expression profile of at least, 2, 3, 4, 5, 6, 7, 8, 9 or 10 genes in the group is observed. ### Claim 7 (depends on 1) The method of claim 1, wherein the expression profile of the test mammalian cell is observed using a computer system comprising a processor element and a memory storage element adapted to process and store data from one or more expression profiles. ### Claim 8 (depends on 1) The method of claim 1, wherein the test mammalian cell or the control mammalian cell is a leukocyte obtained from the peripheral blood. ### Claim 9 (depends on 1) The method of claim 1, wherein the test mammalian cell is obtained from an individual previously identified as exhibiting restricted repetitive behaviors or speech delay. ### Claim 10 (depends on 1) The method of claim 1, wherein the control mammalian cell is obtained from an individual previously identified as not exhibiting restricted repetitive behaviors or speech delay. ### Claim 11 (depends on 1) The method of claim 1, wherein the test mammalian cell and the control mammalian cell are obtained from individuals who are related as siblings or as a parent and a child. ### Claim 12 (depends on 1) The method of claim 1, wherein the test mammalian cell is obtained from an individual identified as having a family member previously identified as exhibiting restricted repetitive behaviors or speech delay. ### Claim 13 (depends on 1) The method of claim 1, wherein the test mammalian cell is obtained from an individual where at least one evaluation is performed from a diagnostic procedure for autism comprising: (a) a Autism Diagnostic Interview (ADI-R); (b) an Autism Diagnostic Observation Schedule (ADOS); (c) an IQ surrogate test based on Raven's Progressive Matrices; or (d) observations of restricted repetitive behaviors or speech delay. ### Claim 14 (depends on 13) The method of claim 13, wherein the at least one evaluation is performed prior to observing the expression profile of the at least one gene. ### Claim 15 A kit comprising: a container; a primer composition contained within said container, wherein the primer composition includes a polymerase chain reaction (PCR) primer effective in the quantitative real time analysis of the mRNA expression levels of one or more genes selected from the group consisting of SEQ ID NOs: 1-44; and a buffer composition. ### Claim 16 (depends on 15) The kit of claim 15, wherein the kit comprises a plurality of chain reaction (PCR) primers effective in the quantitative real time analysis of the mRNA expression levels of different genes selected from the group consisting of SEQ ID NOs: 1-44. ### Claim 17 (depends on 15) The kit of claim 15, further comprising a computer readable a memory storage element adapted to process and store data from one or more expression profiles. ### Claim 18 (depends on 17) The kit of claim 17, wherein the memory storage element organizes expression profile data into a format adapted for electronic comparisons with a library of expression profile data. ### Claim 19 (depends on 1) The kit of claim 1, wherein the primer is adapted to bind to mRNA expressed by a human leukocyte. ### Claim 20 A method of observing an effect of a compound on an expression profile of at least one gene comprising a sequence selected from the group consisting of SEQ ID NOs: 1-44, the method comprising the steps of: observing an expression profile of the at least one gene in the presence of the compound; and comparing the expression profile that is observed in the presence of the compound with the expression profile that is observed in the absence of the compound; so that the effect of the compound on an expression profile of the at least one gene is observed.